Beder Levent Bekir, Gunduz Mehmet, Hotomi Muneki, Fujihara Keiji, Shimada Jun, Tamura Shinji, Gunduz Esra, Fukushima Kunihiro, Yaykasli Kursat, Grenman Reidar, Shimizu Kenji, Yamanaka Noboru
Department of Otolaryngology Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan.
Cancer Sci. 2009 May;100(5):873-80. doi: 10.1111/j.1349-7006.2009.01132.x.
Previous gene expression profiles revealed the T-lymphocyte maturation-associated protein (MAL) gene as being frequently downregulated in head and neck cancer. To define the relationship between the MAL gene and the metastatic process, we evaluated the expression status of the gene in matched primary and metastatic tumors of head and neck cancer by semiquantitative reverse transcription-polymerase chain reaction. Furthermore, we aimed to identify potential genetic and epigenetic mechanisms associated with downregulation of MAL, including loss of heterozygosity (LOH), mutation, and hypermethylation. Thirty-five cell lines of University of Turko squamous cell carcinoma (UT-SCC) series derived from head and neck cancer, including nine pairs from matched primary and metastatic tumors, and 30 pairs of matched primary and metastatic tumor samples were analyzed. Twenty out of 35 (57%) cell lines showed downregulation of MAL expression, whereas no expression was found in 10 cell lines (29%). Considering matched primary and metastatic tumor-derived cell-line pairs, four pairs showed decreased expression only in metastasis-derived cells compared with their primary counterparts. Expression analysis of 21 tissue samples demonstrated decreased or no expression of MAL mRNA in 43% of metastatic tumors compared with matched primary tumors. Relating to mechanisms of downregulation, LOH was observed in 30% of primary tumors and 38% of their metastatic counterparts by a MAL-specific microsatellite marker. Furthermore, we found restoration of MAL mRNA after treatment with demethylating agent (5-aza-2'-deoxycytidine) in 9 (45%) out of 20 cell lines. No mutation was found in UT-SCC cell lines. In conclusion, our findings indicate selective downregulation of MAL expression in metastatic cells, suggesting the MAL gene as a new metastasis-suppressor candidate for head and neck cancer. LOH and hypermethylation appeared to be important mechanisms for inactivation of MAL function.
先前的基因表达谱显示,T淋巴细胞成熟相关蛋白(MAL)基因在头颈癌中经常下调。为了明确MAL基因与转移过程之间的关系,我们通过半定量逆转录-聚合酶链反应评估了该基因在头颈癌原发肿瘤和转移瘤配对样本中的表达状态。此外,我们旨在确定与MAL下调相关的潜在遗传和表观遗传机制,包括杂合性缺失(LOH)、突变和高甲基化。分析了来自头颈癌的35株土耳其中大学鳞状细胞癌(UT-SCC)系列细胞系,包括9对原发肿瘤和转移瘤配对样本,以及30对原发肿瘤和转移瘤配对组织样本。35株细胞系中有20株(57%)显示MAL表达下调,10株细胞系(29%)未检测到表达。在原发肿瘤和转移瘤来源的配对细胞系中,4对转移瘤来源的细胞系与其原发对应细胞相比仅显示表达降低。对21份组织样本的表达分析表明,与配对的原发肿瘤相比,43%的转移瘤中MAL mRNA表达降低或无表达。关于下调机制,通过MAL特异性微卫星标记在30%的原发肿瘤及其38%的转移对应物中观察到LOH。此外,我们发现20株细胞系中有9株(45%)在用去甲基化剂(5-氮杂-2'-脱氧胞苷)处理后MAL mRNA得到恢复。在UT-SCC细胞系中未发现突变。总之,我们的研究结果表明转移细胞中MAL表达存在选择性下调,提示MAL基因是头颈癌新的转移抑制候选基因。LOH和高甲基化似乎是MAL功能失活的重要机制。